Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea ...

The new CEO Richard Ascroft brings more than 30 years of industry experience, including senior roles at Takeda ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and ...

GS-1811, a potential first-in-class immunotherapy, is designed to target and deplete immunosuppressive Tregs in the tumor ...

Scientists from Cincinnati Children's and colleagues based in Japan report achieving a major step forward in organoid ...

Saatchi & Saatchi Wellness announced Wednesday the appointments of three new leaders: Brendan Gallagher as president, Divya Dileep as chief creative officer and Beth Bour as the agency’s first-ever ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...